Jasper Therapeutics (JSPR) Stock Forecast, Price Target & Predictions
JSPR Stock Forecast
Jasper Therapeutics stock forecast is as follows: an average price target of $34.75 (represents a 86.53% upside from JSPR’s last price of $18.63) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
JSPR Price Target
The average price target for Jasper Therapeutics (JSPR) is $34.75 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $65.00 to $3.00. This represents a potential 86.53% upside from JSPR's last price of $18.63.
JSPR Analyst Ratings
According to 7 Wall Street analysts, Jasper Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for JSPR stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Jasper Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 06, 2024 | Emily Bodnar | H.C. Wainwright | $65.00 | $24.52 | 165.09% | 248.90% |
| Apr 03, 2024 | Gavin Clark-Gartner | Evercore ISI | $65.00 | $26.20 | 148.09% | 248.90% |
| Feb 07, 2023 | - | Cantor Fitzgerald | $6.00 | $1.92 | 212.50% | -67.79% |
| Jan 11, 2023 | - | Credit Suisse | $3.00 | $1.65 | 81.82% | -83.90% |
The latest Jasper Therapeutics stock forecast, released on May 06, 2024 by Emily Bodnar from H.C. Wainwright, set a price target of $65.00, which represents a 165.09% increase from the stock price at the time of the forecast ($24.52), and a 248.90% increase from JSPR last price ($18.63).
Jasper Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $65.00 |
| Last Closing Price | $18.63 | $18.63 | $18.63 |
| Upside/Downside | -100.00% | -100.00% | 248.90% |
In the current month, the average price target of Jasper Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Jasper Therapeutics's last price of $18.63. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jul 08, 2024 | BTIG | - | Buy | Initialise |
| Jun 25, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 06, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Apr 03, 2024 | Evercore ISI | - | Outperform | Initialise |
| Mar 27, 2024 | RBC Capital | - | Outperform | Initialise |
| Feb 07, 2023 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Nov 14, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Feb 28, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
| Feb 25, 2022 | Credit Suisse | Outperform | Outperform | Hold |
Jasper Therapeutics's last stock rating was published by RBC Capital on Aug 14, 2024. The company gave JSPR a "Outperform" rating, the same as its previous rate.
Jasper Therapeutics Financial Forecast
Jasper Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Jasper Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. JSPR's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Jasper Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict JSPR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Jasper Therapeutics's previous annual EBITDA (undefined) of $NaN.
Jasper Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-14.41M | $-13.90M | $-13.57M | $-13.05M | $-16.49M | $-15.47M | $-14.55M | $-13.63M | $-16.42M | $-15.96M | $-16.31M |
| High Forecast | $-14.41M | $-13.90M | $-13.57M | $-13.05M | $-16.49M | $-15.47M | $-14.55M | $-13.63M | $-16.42M | $-14.48M | $-16.31M |
| Low Forecast | $-14.41M | $-13.90M | $-13.57M | $-13.05M | $-16.49M | $-15.47M | $-14.55M | $-13.63M | $-16.42M | $-16.99M | $-16.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Jasper Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. JSPR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Jasper Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Jasper Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to JSPR last annual SG&A of $NaN (undefined).
Jasper Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.96 | $-0.93 | $-0.91 | $-0.87 | $-1.10 | $-1.03 | $-0.97 | $-0.91 | $-1.10 | $-1.06 | $-1.09 |
| High Forecast | $-0.96 | $-0.93 | $-0.91 | $-0.87 | $-1.10 | $-1.03 | $-0.97 | $-0.91 | $-1.10 | $-0.97 | $-1.09 |
| Low Forecast | $-0.96 | $-0.93 | $-0.91 | $-0.87 | $-1.10 | $-1.03 | $-0.97 | $-0.91 | $-1.10 | $-1.13 | $-1.09 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Jasper Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to JSPR previous annual EPS of $NaN (undefined).
Jasper Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XLO | Xilio Therapeutics | $0.81 | $7.00 | 764.20% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.22 | $7.00 | 215.32% | Buy |
| INZY | Inozyme Pharma | $4.98 | $14.00 | 181.12% | Buy |
| EWTX | Edgewise Therapeutics | $17.52 | $48.00 | 173.97% | Buy |
| DSGN | Design Therapeutics | $4.67 | $9.67 | 107.07% | Buy |
| JSPR | Jasper Therapeutics | $18.63 | $34.75 | 86.53% | Buy |
| LYRA | Lyra Therapeutics | $0.27 | $0.50 | 85.19% | Hold |
| ORIC | ORIC Pharmaceuticals | $9.65 | $17.00 | 76.17% | Buy |
| ELYM | Eliem Therapeutics | $7.39 | $13.00 | 75.91% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
| HOOK | HOOKIPA Pharma | $4.74 | $3.00 | -36.71% | Buy |
JSPR Forecast FAQ
Is Jasper Therapeutics a good buy?
Yes, according to 7 Wall Street analysts, Jasper Therapeutics (JSPR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of JSPR's total ratings.
What is JSPR's price target?
Jasper Therapeutics (JSPR) average price target is $34.75 with a range of $3 to $65, implying a 86.53% from its last price of $18.63. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Jasper Therapeutics stock go up soon?
According to Wall Street analysts' prediction for JSPR stock, the company can go up by 86.53% (from the last price of $18.63 to the average price target of $34.75), up by 248.90% based on the highest stock price target, and down by -83.90% based on the lowest stock price target.
Can Jasper Therapeutics stock reach $30?
JSPR's average twelve months analyst stock price target of $34.75 supports the claim that Jasper Therapeutics can reach $30 in the near future.
What are Jasper Therapeutics's analysts' financial forecasts?
Jasper Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-60.14M (high $-60.14M, low $-60.14M), average SG&A $0 (high $0, low $0), and average EPS is $-4.013 (high $-4.013, low $-4.013). JSPR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-54.924M (high $-54.924M, low $-54.924M), average SG&A $0 (high $0, low $0), and average EPS is $-3.665 (high $-3.665, low $-3.665).